NASDAQ:IMRX Immuneering (IMRX) Stock Forecast, Price & News $10.60 +0.34 (+3.31%) (As of 01:28 PM ET) Add Compare Share Share Today's Range$10.08▼$10.8450-Day Range$6.49▼$13.3652-Week Range$3.70▼$16.17Volume22,723 shsAverage Volume59,280 shsMarket Capitalization$310.05 millionP/E RatioN/ADividend YieldN/APrice Target$18.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Immuneering MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside76.1% Upside$18.67 Price TargetShort InterestBearish7.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.15) to ($2.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.79 out of 5 starsMedical Sector716th out of 986 stocksPharmaceutical Preparations Industry339th out of 480 stocks 3.3 Analyst's Opinion Consensus RatingImmuneering has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.67, Immuneering has a forecasted upside of 76.1% from its current price of $10.60.Amount of Analyst CoverageImmuneering has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted7.42% of the float of Immuneering has been sold short.Short Interest Ratio / Days to CoverImmuneering has a short interest ratio ("days to cover") of 24, which indicates bearish sentiment.Change versus previous monthShort interest in Immuneering has recently increased by 25.60%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmuneering does not currently pay a dividend.Dividend GrowthImmuneering does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMRX. Previous Next 2.4 News and Social Media Coverage News SentimentImmuneering has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Immuneering this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immuneering insiders have not sold or bought any company stock.Percentage Held by Insiders23.90% of the stock of Immuneering is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.70% of the stock of Immuneering is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Immuneering are expected to grow in the coming year, from ($2.15) to ($2.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immuneering is -5.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immuneering is -5.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmuneering has a P/B Ratio of 2.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Immuneering (NASDAQ:IMRX) StockImmuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.Read More Receive IMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter. Email Address IMRX Stock News HeadlinesJune 5, 2023 | finance.yahoo.comImmuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid TumorsMay 5, 2023 | finance.yahoo.comImmuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue EstimatesJune 9, 2023 | Edge On The Street (Ad)Graphite versus Lithium - What Investors Should KnowOver 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.May 4, 2023 | finance.yahoo.comImmuneering Reports First Quarter 2023 Financial Results and Provides Business UpdatesMay 4, 2023 | markets.businessinsider.comMizuho Securities Sticks to Its Buy Rating for Immuneering (IMRX)May 2, 2023 | americanbankingnews.comShort Interest in Immuneering Co. (NASDAQ:IMRX) Rises By 6.1%April 25, 2023 | americanbankingnews.comChardan Capital Weighs in on Immuneering Co.'s FY2023 Earnings (NASDAQ:IMRX)April 21, 2023 | benzinga.comIs Immuneering Corp (IMRX) a Stock to Watch After Gaining 4.09% This Week?June 9, 2023 | PressReach (Ad)This Stock's Worth ResearchingUncover the buzz behind this trending stock. Read the comprehensive report here.April 21, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Immuneering Co. (NASDAQ:IMRX) Increased by OppenheimerApril 20, 2023 | msn.comMorgan Stanley Upgrades Immuneering Corp (IMRX)April 20, 2023 | msn.comMizuho Upgrades Immuneering Corp (IMRX)April 20, 2023 | americanbankingnews.comImmuneering (NASDAQ:IMRX) PT Raised to $22.00April 19, 2023 | msn.comImmuneering Picks Up New Kudos but Still FaltersApril 19, 2023 | msn.comWhat 7 Analyst Ratings Have To Say About ImmuneeringApril 19, 2023 | markets.businessinsider.comImmuneering (IMRX) was upgraded to a Hold Rating at Morgan StanleyApril 19, 2023 | msn.comImmuneering gains as Morgan Stanley, Mizuho upgrade on lead assetApril 19, 2023 | americanbankingnews.comImmuneering (NASDAQ:IMRX) Upgraded at Morgan StanleyApril 19, 2023 | americanbankingnews.comImmuneering (NASDAQ:IMRX) Stock Rating Upgraded by MizuhoApril 19, 2023 | markets.businessinsider.comImmuneering (IMRX) was upgraded to a Buy Rating at Mizuho SecuritiesApril 18, 2023 | finance.yahoo.comImmuneering Announces $30 Million Underwritten OfferingApril 12, 2023 | finance.yahoo.comImmuneering to Present at the 22nd Annual Needham Virtual Healthcare ConferenceApril 11, 2023 | finance.yahoo.comImmuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains?April 5, 2023 | finance.yahoo.comImmuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023March 31, 2023 | americanbankingnews.comImmuneering (NASDAQ:IMRX) Now Covered by MizuhoMarch 31, 2023 | msn.comMizuho Initiates Coverage of Immuneering (IMRX) with Neutral RecommendationMarch 29, 2023 | markets.businessinsider.comImmuneering (IMRX) Receives a New Rating from Mizuho SecuritiesSee More Headlines IMRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMRX Company Calendar Last Earnings11/08/2021Today6/09/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IMRX CUSIPN/A CIK1790340 Webwww.immuneering.com Phone617-500-8080FaxN/AEmployees64Year FoundedN/APrice Target and Rating Average Stock Price Forecast$18.67 High Stock Price Forecast$22.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+77.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,510,000.00 Net Margins-15,934.70% Pretax Margin-38,512.78% Return on Equity-44.23% Return on Assets-40.50% Debt Debt-to-Equity RatioN/A Current Ratio17.05 Quick Ratio17.05 Sales & Book Value Annual Sales$320,000.00 Price / Sales960.68 Cash FlowN/A Price / Cash FlowN/A Book Value$4.16 per share Price / Book2.53Miscellaneous Outstanding Shares29,250,000Free Float22,258,000Market Cap$307.42 million OptionableNot Optionable Beta-1.35 Key ExecutivesDr. Benjamin J. Zeskind M.B.A. (Age 39)MBA, Ph.D., Co-Founder, Pres, CEO & Director Comp: $839.77kDr. Brett M. Hall Ph.D. (Age 54)Chief Scientific Officer Comp: $819.69kMs. Mallory Morales CPA (Age 39)VP of Fin., Principal Financial & Accounting Officer and Treasurer Ms. Paula George CPASr. Mang. of Accounting & OperationsMr. Michael D. Bookman J.D. (Age 34)Gen. Counsel & Sec. Ms. Leah R. NeufeldChief People OfficerDr. Scott Barrett M.D. (Age 59)Chief Medical Officer Dr. Mohamedi Kagalwala M.B.A.Ph.D., Head of Neuroscience Devel.Dr. Peter King Ph.D.Head of Discovery & VPDr. Rajaraman Krishnan Ph.D.Head of Neuroscience DiscoveryMore ExecutivesKey CompetitorsKaryopharm TherapeuticsNASDAQ:KPTIInozyme PharmaNASDAQ:INZYPrelude TherapeuticsNASDAQ:PRLDAcrivon TherapeuticsNASDAQ:ACRVI-MabNASDAQ:IMABView All CompetitorsInstitutional OwnershipSusquehanna International Group LLPBought 12,949 shares on 5/16/2023Ownership: 0.198%Jane Street Group LLCBought 46,571 shares on 5/16/2023Ownership: 0.159%Price T Rowe Associates Inc. MDSold 161,192 shares on 5/15/2023Ownership: 11.824%BlackRock Inc.Sold 8,191 shares on 5/12/2023Ownership: 4.582%UBS Group AGBought 2,713 shares on 5/12/2023Ownership: 0.009%View All Institutional Transactions IMRX Stock - Frequently Asked Questions Should I buy or sell Immuneering stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immuneering in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMRX shares. View IMRX analyst ratings or view top-rated stocks. What is Immuneering's stock price forecast for 2023? 3 Wall Street research analysts have issued 1 year price targets for Immuneering's shares. Their IMRX share price forecasts range from $14.00 to $22.00. On average, they anticipate the company's share price to reach $18.67 in the next year. This suggests a possible upside of 77.6% from the stock's current price. View analysts price targets for IMRX or view top-rated stocks among Wall Street analysts. How have IMRX shares performed in 2023? Immuneering's stock was trading at $4.85 at the start of the year. Since then, IMRX stock has increased by 116.7% and is now trading at $10.51. View the best growth stocks for 2023 here. Are investors shorting Immuneering? Immuneering saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,570,000 shares, an increase of 25.6% from the April 30th total of 1,250,000 shares. Based on an average daily trading volume, of 65,400 shares, the days-to-cover ratio is currently 24.0 days. Currently, 7.4% of the shares of the company are short sold. View Immuneering's Short Interest. When is Immuneering's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our IMRX earnings forecast. How were Immuneering's earnings last quarter? Immuneering Co. (NASDAQ:IMRX) issued its quarterly earnings results on Monday, November, 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.10. The business had revenue of $0.48 million for the quarter, compared to analyst estimates of $0.70 million. Immuneering had a negative trailing twelve-month return on equity of 44.23% and a negative net margin of 15,934.70%. When did Immuneering IPO? (IMRX) raised $105 million in an IPO on Friday, July 30th 2021. The company issued 7,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities acted as the underwriters for the IPO. What is Immuneering's stock symbol? Immuneering trades on the NASDAQ under the ticker symbol "IMRX." Who are Immuneering's major shareholders? Immuneering's stock is owned by a variety of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (11.82%), BlackRock Inc. (4.58%), FMR LLC (1.38%), ExodusPoint Capital Management LP (0.30%), Susquehanna International Group LLP (0.20%) and Jane Street Group LLC (0.16%). Insiders that own company stock include Ann E Berman, Benjamin J Zeskind, Biren Amin, Brett Matthew Hall, Laurie Keating, Michael Bookman and Scott Barrett. View institutional ownership trends. How do I buy shares of Immuneering? Shares of IMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Immuneering's stock price today? One share of IMRX stock can currently be purchased for approximately $10.51. How much money does Immuneering make? Immuneering (NASDAQ:IMRX) has a market capitalization of $307.42 million and generates $320,000.00 in revenue each year. The company earns $-50,510,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. How can I contact Immuneering? The official website for the company is www.immuneering.com. The company can be reached via phone at 617-500-8080 or via email at afields@rxir.com. This page (NASDAQ:IMRX) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.